F → Genentec'

+8509529882

P.01/01 F-824

Sheet 1 of 1

MAR 0 5 2001

U.S. Dept of Commerce

Serial No. Atty Docket No.

FORM PTO-1449 Patent and Trademark Office 09/273,230 P0998D1 Applicant LIST OF DISCLOSURES CITED BY APPLICANT Claland et al. Filing Date Group (Use several sheets if necessary) 18 Mar 1999 1642 U.S. PATENT DOCUMENTS Examiner Class Subclass Filing Date Date Name Document Number initials 6,165,464 26,12,00 Hudziak et al. 248 OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Combs at al., "Comparative efficacy of Herceptin in the nude mouse tumor xenograft model: IV bolus versus subcutaneous infusion" (Poster presented at the November 1999 AAPS National Meeting) (1999) 249 Kern et al. . Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. American Journal of Resolvatory Cell & Molecular Biology 9(4):448-454 (Oct 1993) 250 Ohnishi et al . Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal artibody" British Journal of Cancer 71(5):969-973 (May 1995) 261 Tokuda er al . 'In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product' <u>British Journal of Cancer</u> 73(11):1362-1365 (Jun 1996) 252 Date Considered Examiner

whether or not citation is in conformance with MPEP 609, draw line through citation *Examiner Initial if reference considered, if not in conformance and not considered. Include copy of this form with next communication to applicant.